Caris Life Sciences said its second-quarter 2026 financial results showed strong top-line momentum, and the company also lifted its revenue guidance for the full year. The update points to continued expansion in its core molecular profiling business during the quarter.
According to the company, revenue rose 45%, helped by solid performance in molecular profiling services. Caris said that activity included about 59,200 clinical cases, highlighting the scale of testing demand in the period.
The quarter also included more than 114,000 whole exome and whole transcriptome tests, along with over 345,000 total oncology tests. Those figures indicate broad use of the company’s precision oncology testing offerings across its clinical workflow.
By increasing its 2026 revenue outlook, Caris signaled confidence that current business trends can continue through the rest of the year. The results suggest that molecular profiling remains the main driver of growth as the company expands testing volume and oncology-related services.
